Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Artelo Biosciences, Inc. (ARTL)
USD1.15
-0.01 (-0.86%)
US NASDAQ Healthcare Biotechnology
Address
505 Lomas Santa Fe 92075
Solana Beach, CA, US
Solana Beach, CA, US
CEO
Gregory D. Gorgas
Website
artelobio.com
IPO
2019-06-21
CIK 1621221 ISIN US04301G7060
Also trades on
NASDAQ Capital Market · ARTL (USD)
NASDAQ Capital Market · ARTLW (USD)
Description
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.15
-0.01 (-0.86%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
-0.11
Float Shares
2.17M
Free Float %
99.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.30% | -11.03% | -56.75% | -35.00% | +26.49% | +91.80% | -60.80% | -77.19% | -97.66% | -99.44% | -99.44% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
1.15
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-9.74
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-438.1% Q1'26: -1,566.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-75.6% ★ Q1'26: -92.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.06× Q1'26: -0.07× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
49.29M
49.29M – 49.29M
|
99.56M
99.56M – 99.56M
+102.0% YoY
|
184.73M
184.73M – 184.73M
+85.5% YoY
|
245.30M
245.30M – 245.30M
+32.8% YoY
|
| EBITDA |
-10.11M
|
-12.54M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-10.11M
|
-12.69M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-9.83M
est: -38.10M (+74.2%)
|
-12.88M
est: -85.61M (+85.0%)
|
-23.19M
-23.19M – -23.19M
+72.9% YoY
|
-12.44M
-12.44M – -12.44M
+46.3% YoY
|
29.69M
29.69M – 29.69M
+338.6% YoY
|
71.05M
71.05M – 71.05M
+139.3% YoY
|
95.72M
95.72M – 95.72M
+34.7% YoY
|
| SGA |
4.12M
|
5.98M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.02
est: -11.82 (+91.4%)
|
-5.47
est: -36.33 (+84.9%)
|
-9.84
-9.84 – -9.84
+72.9% YoY
|
-5.28
-5.28 – -5.28
+46.3% YoY
|
12.60
12.60 – 12.60
+338.6% YoY
|
30.15
30.15 – 30.15
+139.3% YoY
|
40.62
40.62 – 40.62
+34.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
29
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CCZG LLC | 1.20M | 7.64% | — | 1.20M | — | 1.20M | HC | Delaware | 2021-03-01 | ↗ |
| 2 | Parian Global Management LP | 1.20M | 7.64% | — | 1.20M | — | 1.20M | IA | Delaware | 2021-03-01 | ↗ |
| 3 | Zachary C. Miller | 1.20M | 7.64% | — | 1.20M | — | 1.20M | HC, IN | Delaware | 2021-03-01 | ↗ |
| 4 | Parian Global Master Fund LP | 921.5K | 5.87% | — | 921.5K | — | 921.5K | PN | Delaware | 2021-03-01 | ↗ |
| 5 | Empery Asset Management, LP | 920.0K | 4.99% | — | 920.0K | — | — | PN | Delaware | 2021-01-13 | ↗ |
| 6 | Martin D. Hoe | 920.0K | 4.99% | — | 920.0K | — | — | IN | Delaware | 2021-01-13 | ↗ |
| 7 | Ryan M. Lane | 920.0K | 4.99% | — | 920.0K | — | — | IN | Delaware | 2021-01-13 | ↗ |
| 8 | Michael Bigger | 900.0K | 4.99% | — | — | — | 900.0K | IN | Delaware | 2021-02-10 | ↗ |
| 9 | Adam J. Chill | 800.0K | 4.99% | — | 800.0K | — | — | IN | Delaware | 2021-02-05 | ↗ |
| 10 | Ari Storch | 800.0K | 4.99% | — | 800.0K | — | — | IN | Delaware | 2021-02-05 | ↗ |
| 11 | Kingsbrook Opportunities GP LLC | 800.0K | 4.99% | — | 800.0K | — | — | OO | Delaware | 2021-02-05 | ↗ |
| 12 | Kingsbrook Opportunities Master Fund LP | 800.0K | 4.99% | — | 800.0K | — | — | PN | Delaware | 2021-02-05 | ↗ |
| 13 | Kingsbrook Partners LP | 800.0K | 4.99% | — | 800.0K | — | — | PN | Delaware | 2021-02-05 | ↗ |
| 14 | Scott Wallace | 800.0K | 4.99% | — | 800.0K | — | — | IN | Delaware | 2021-02-05 | ↗ |
| 15 | CVI Investments, Inc. | 793.7K | 4.90% | — | 793.7K | — | 793.7K | CO | Cayman Islands | 2021-02-16 | ↗ |
| 16 | Bigger Capital Fund GP, LLC | 450.0K | 2.80% | — | — | — | 450.0K | OO | Delaware | 2021-02-10 | ↗ |
| 17 | Bigger Capital Fund, LP | 450.0K | 2.80% | — | — | — | 450.0K | PN | Delaware | 2021-02-10 | ↗ |
| 18 | District 2 Capital Fund LP | 450.0K | 2.80% | — | — | — | 450.0K | PN | Delaware | 2021-02-10 | ↗ |
| 19 | District 2 Capital LP | 450.0K | 2.80% | — | — | — | 450.0K | PN | Delaware | 2021-02-10 | ↗ |
| 20 | District 2 GP LLC | 450.0K | 2.80% | — | — | — | 450.0K | OO | Delaware | 2021-02-10 | ↗ |
| 21 | District 2 Holdings LLC | 450.0K | 2.80% | — | — | — | 450.0K | OO | Delaware | 2021-02-10 | ↗ |
| 22 | Iroquois Capital Management L.L.C. | 100.0K | 0.24% | — | 100.0K | — | — | OO | Delaware | 2022-02-23 | ↗ |
| 23 | Kimberly Page | 100.0K | 0.24% | — | 100.0K | — | — | IN | Delaware | 2022-02-23 | ↗ |
| 24 | Richard Abbe | 100.0K | 0.24% | — | 100.0K | — | — | HC, IN | Delaware | 2022-02-23 | ↗ |
| 25 | Daniel B. Asher | — | 0.00% | — | — | — | — | HC, IN | — | 2020-10-26 | ↗ |
| 26 | Hudson Bay Capital Management LP | — | 0.00% | — | — | — | — | PN | Delaware | 2022-02-04 | ↗ |
| 27 | Intracoastal Capital LLC | — | 0.00% | — | — | — | — | OO | — | 2020-10-26 | ↗ |
| 28 | Mitchell P. Kopin | — | 0.00% | — | — | — | — | HC, IN | — | 2020-10-26 | ↗ |
| 29 | Sander Gerber | — | 0.00% | — | — | — | — | IN | Delaware | 2022-02-04 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 13.9K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.73
Neutral
Ratio by volume
1.24
Neutral
Buys
29
Sells
40
Shares acquired
430.9K
Shares disposed
346.9K
Cash buys
—
Cash sales
—
Net activity
+83,996
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-30 | Reyes Gregory | Director | A-Award | A | Stock Options (right to buy) | 292 | 1.71 | 499.32 | 292 | D | ↗ |
| 2026-01-30 | MATSUI CONNIE | Director | A-Award | A | Stock Options (right to buy) | 292 | 1.71 | 499.32 | 292 | D | ↗ |
| 2026-01-30 | Kelly Steven | Director | A-Award | A | Stock Options (right to buy) | 292 | 1.71 | 499.32 | 292 | D | ↗ |
| 2026-01-30 | FAVORITO TAMARA A | Director | A-Award | A | Stock Options (right to buy) | 292 | 1.71 | 499.32 | 292 | D | ↗ |
| 2026-01-30 | EMANUELE ROBERT MARTIN | Director | A-Award | A | Stock Options (right to buy) | 292 | 1.71 | 499.32 | 292 | D | ↗ |
| 2026-01-30 | Blayney Douglas | Director | A-Award | A | Stock Options (right to buy) | 292 | 1.71 | 499.32 | 292 | D | ↗ |
| 2026-01-29 | Spring Mark Edward | Officer | A-Award | A | Stock Options (right to buy) | 36,391 | 1.68 | 61.1K | 36,391 | D | ↗ |
| 2026-01-29 | Gorgas Gregory D. | Director / Officer | A-Award | A | Stock Options (right to buy) | 154,713 | 1.68 | 259.9K | 154,713 | D | ↗ |
| 2025-11-01 | Spring Mark Edward | Officer | — | — | Stock Option (right to buy) | 2,500 | 11.03 | 27.6K | 0 | D | ↗ |
| 2025-10-28 | MATSUI CONNIE | Director | C-Conversion | A | Convertible Promissory Note | 0 | 3.40 | — | 0 | D | ↗ |
| 2025-10-28 | Gorgas Gregory D. | Director / Officer | C-Conversion | D | Convertible Promissory Note | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-10-28 | FAVORITO TAMARA A | Director | C-Conversion | A | Convertible Promissory Note | 0 | 3.40 | — | 0 | D | ↗ |
| 2025-07-02 | Gorgas Gregory D. | Director / Officer | A-Award | A | Stock Option (right to buy) | 20,393 | 11.03 | 224.9K | 20,393 | D | ↗ |
| 2025-05-01 | MATSUI CONNIE | Director | P-Purchase | A | Convertible Promissory Note | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-05-01 | Gorgas Gregory D. | Director / Officer | P-Purchase | A | Convertible Promissory Note | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-05-01 | FAVORITO TAMARA A | Director | P-Purchase | A | Convertible Promissory Note | 0 | 0.00 | — | 0 | I | ↗ |
| 2024-12-20 | Reyes Gregory | Director | A-Award | A | Stock Option (right to buy) | 1,750 | 0.95 | 1.7K | 1,750 | D | ↗ |
| 2024-12-20 | MATSUI CONNIE | Director | A-Award | A | Stock Option (right to buy) | 1,750 | 0.95 | 1.7K | 1,750 | D | ↗ |
| 2024-12-20 | Kelly Steven | Director | A-Award | A | Stock Option (right to buy) | 1,750 | 0.95 | 1.7K | 1,750 | D | ↗ |
| 2024-12-20 | FAVORITO TAMARA A | Director | A-Award | A | Stock Option (right to buy) | 1,750 | 0.95 | 1.7K | 1,750 | D | ↗ |
| 2024-12-20 | EMANUELE ROBERT MARTIN | Director | A-Award | A | Stock Option (right to buy) | 1,750 | 0.95 | 1.7K | 1,750 | D | ↗ |
| 2024-12-20 | Blayney Douglas | Director | A-Award | A | Stock Option (right to buy) | 1,750 | 0.95 | 1.7K | 1,750 | D | ↗ |
| 2024-02-28 | Reyes Gregory | Director | D-Return | D | Stock Option (right to buy) | 8,000 | 9.05 | 72.4K | 0 | — | ↗ |
| 2024-02-28 | MATSUI CONNIE | Director | D-Return | D | Stock Option (right to buy) | 1,767 | 29.85 | 52.7K | 0 | — | ↗ |
| 2024-02-28 | Kelly Steven | Director | D-Return | D | Stock Option (right to buy) | 667 | 15.00 | 10.0K | 0 | — | ↗ |
| 2024-02-28 | Gorgas Gregory D. | Director / Officer | D-Return | D | Stock Option (right to buy) | 90,334 | 9.45 | 853.7K | 0 | — | ↗ |
| 2024-02-28 | FAVORITO TAMARA A | Director | D-Return | D | Stock Option (right to buy) | 667 | 4.89 | 3.3K | 0 | — | ↗ |
| 2024-02-28 | EMANUELE ROBERT MARTIN | Director | D-Return | D | Stock Option (right to buy) | 834 | 162.00 | 135.1K | 0 | — | ↗ |
| 2024-02-28 | Blayney Douglas | Director | A-Award | A | Stock Option (right to buy) | 667 | 1.55 | 1.0K | 667 | — | ↗ |
| 2024-01-05 | Gorgas Gregory D. | Director / Officer | A-Award | A | Stock Option (right to buy) | 92,000 | 1.49 | 137.1K | 92,000 | — | ↗ |
| 2023-08-04 | Reyes Gregory | Director | A-Award | A | Stock Option (right to buy) | 1,083 | 2.01 | 2.2K | 1,083 | — | ↗ |
| 2023-08-04 | MATSUI CONNIE | Director | A-Award | A | Stock Option (right to buy) | 1,083 | 2.01 | 2.2K | 1,083 | — | ↗ |
| 2023-08-04 | Kelly Steven | Director | A-Award | A | Stock Option (right to buy) | 1,083 | 2.01 | 2.2K | 1,083 | — | ↗ |
| 2023-08-04 | FAVORITO TAMARA A | Director | A-Award | A | Stock Option (right to buy) | 1,083 | 2.01 | 2.2K | 1,083 | — | ↗ |
| 2023-08-04 | EMANUELE ROBERT MARTIN | Director | A-Award | A | Stock Option (right to buy) | 1,083 | 2.01 | 2.2K | 1,083 | — | ↗ |
| 2023-08-04 | Blayney Douglas | Director | A-Award | A | Stock Option (right to buy) | 1,083 | 2.01 | 2.2K | 1,083 | — | ↗ |
| 2023-06-30 | Reyes Gregory | Director | A-Award | A | Stock Option (right to buy) | 667 | 2.01 | 1.3K | 667 | — | ↗ |
| 2023-06-30 | MATSUI CONNIE | Director | A-Award | A | Stock Option (right to buy) | 667 | 2.01 | 1.3K | 667 | — | ↗ |
| 2023-06-30 | Kelly Steven | Director | A-Award | A | Stock Option (right to buy) | 667 | 2.01 | 1.3K | 667 | — | ↗ |
| 2023-06-30 | FAVORITO TAMARA A | Director | A-Award | A | Stock Option (right to buy) | 667 | 2.01 | 1.3K | 667 | — | ↗ |
| 2023-06-30 | EMANUELE ROBERT MARTIN | Director | A-Award | A | Stock Option (right to buy) | 667 | 2.01 | 1.3K | 667 | — | ↗ |
| 2023-06-30 | Blayney Douglas | Director | A-Award | A | Stock Option (right to buy) | 667 | 2.01 | 1.3K | 667 | — | ↗ |
| 2023-02-01 | Gorgas Gregory D. | Director / Officer | A-Award | A | Stock Option (right to buy) | 85,000 | 3.15 | 267.8K | 85,000 | — | ↗ |
| 2022-08-12 | Gorgas Gregory D. | Director | P-Purchase | A | Common Stock | 1,200 | 4.00 | 4.8K | 2,400 | — | ↗ |
| 2022-08-11 | Gorgas Gregory D. | Director | P-Purchase | A | Common Stock | 1,200 | 4.03 | 4.8K | 1,200 | — | ↗ |
| 2022-06-24 | SEYMOUR TAMARA A | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-06-24 | Reyes Gregory | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-06-24 | MATSUI CONNIE | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 0.33 | 3.3K | 10,000 | — | ↗ |
| 2022-06-24 | Kelly Steven | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 0.33 | 3.3K | 10,000 | — | ↗ |
| 2022-06-24 | EMANUELE ROBERT MARTIN | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-06-24 | Blayney Douglas | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2021-12-03 | Gorgas Gregory D. | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,355,000 | 0.63 | 853.7K | 1,355,000 | — | ↗ |
| 2021-07-16 | SEYMOUR TAMARA A | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 1.00 | 10.0K | 10,000 | — | ↗ |
| 2021-07-16 | Reyes Gregory | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 1.00 | 10.0K | 10,000 | — | ↗ |
| 2021-07-16 | MATSUI CONNIE | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 1.00 | 10.0K | 10,000 | — | ↗ |
| 2021-07-16 | Kelly Steven | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 1.00 | 10.0K | 10,000 | — | ↗ |
| 2021-07-16 | EMANUELE ROBERT MARTIN | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 1.00 | 10.0K | 10,000 | — | ↗ |
| 2021-07-16 | Blayney Douglas | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 1.00 | 10.0K | 10,000 | — | ↗ |
| 2021-07-16 | Beck John W | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 1.00 | 10.0K | 10,000 | — | ↗ |
| 2021-04-16 | Gorgas Gregory D. | Director / Officer | P-Purchase | A | Common Stock | 8,500 | 1.15 | 9.8K | 270,676 | — | ↗ |
| 2021-03-05 | SEYMOUR TAMARA A | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 1.52 | 45.6K | 30,000 | — | ↗ |
| 2021-03-05 | Gorgas Gregory D. | Director / Officer | A-Award | A | Stock Option (right to buy) | 575,100 | 1.52 | 874.2K | 575,100 | — | ↗ |
| 2021-03-03 | SEYMOUR TAMARA A | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-12 | MATSUI CONNIE | Director | A-Award | A | Stock Option (right to buy) | 159,500 | 2.66 | 424.3K | 159,500 | — | ↗ |
| 2021-02-12 | Kelly Steven | Director | A-Award | A | Stock Option (right to buy) | 144,500 | 2.66 | 384.4K | 144,500 | — | ↗ |
| 2021-02-12 | Gorgas Gregory D. | Director / Officer | A-Award | A | Stock Option (right to buy) | 834,500 | 2.66 | 2.22M | 834,500 | — | ↗ |
| 2021-02-12 | EMANUELE ROBERT MARTIN | Director | A-Award | A | Stock Option (right to buy) | 120,500 | 2.66 | 320.5K | 120,500 | — | ↗ |
| 2021-02-12 | Blayney Douglas | Director | A-Award | A | Stock Option (right to buy) | 139,500 | 2.66 | 371.1K | 139,500 | — | ↗ |
| 2021-02-12 | Beck John W | Director | A-Award | A | Stock Option (right to buy) | 141,500 | 2.66 | 376.4K | 141,500 | — | ↗ |
| 2020-12-04 | Reyes Gregory | Director | A-Award | A | Stock Option (right to buy) | 120,000 | 0.60 | 72.4K | 120,000 | — | ↗ |
| 2020-11-30 | Reyes Gregory | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-05-15 | Gorgas Gregory D. | Director / Officer | P-Purchase | A | Common Stock | 4,200 | 1.21 | 5.1K | 262,176 | — | ↗ |
| 2020-05-04 | MATSUI CONNIE | Director | P-Purchase | A | Common Stock | 41,667 | 1.20 | 50.0K | 56,667 | — | ↗ |
| 2020-05-04 | Gorgas Gregory D. | Director / Officer | P-Purchase | A | Common Stock | 4,167 | 1.20 | 5.0K | 257,976 | — | ↗ |
| 2019-12-06 | Beck John W | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-11-04 | Gorgas Gregory D. | Director / Officer | P-Purchase | A | Common Stock | 2,400 | 2.21 | 5.3K | 253,809 | — | ↗ |
| 2019-11-01 | Gorgas Gregory D. | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 2.28 | 5.7K | 251,409 | — | ↗ |
| 2019-10-31 | Gorgas Gregory D. | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 1.95 | 4.9K | 248,909 | — | ↗ |
| 2019-10-30 | Gorgas Gregory D. | Director / Officer | P-Purchase | A | Common Stock | 2,600 | 1.99 | 5.2K | 246,409 | — | ↗ |
| 2019-10-15 | Gorgas Gregory D. | Director / Officer | P-Purchase | A | Common Stock | 2,600 | 2.05 | 5.3K | 243,809 | — | ↗ |
| 2019-10-11 | Gorgas Gregory D. | Director / Officer | P-Purchase | A | Common Stock | 2,700 | 1.96 | 5.3K | 241,209 | — | ↗ |
| 2019-09-04 | O'Brien Peter Michael | 10% Owner | J-Other | D | Common Stock | 17,500 | 0.00 | — | 7,500 | — | ↗ |
| 2019-08-29 | MATSUI CONNIE | Director | A-Award | A | Stock Option (right to buy) | 26,500 | 1.99 | 52.7K | 26,500 | — | ↗ |
| 2019-08-29 | Kelly Steven | Director | A-Award | A | Stock Option (right to buy) | 22,250 | 1.99 | 44.3K | 22,250 | — | ↗ |
| 2019-08-29 | Gorgas Gregory D. | Director / Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 1.99 | 149.3K | 75,000 | — | ↗ |
| 2019-08-29 | Erbez Georgia | Director | A-Award | A | Stock Option (right to buy) | 22,250 | 1.99 | 44.3K | 22,250 | — | ↗ |
| 2019-08-29 | EMANUELE ROBERT MARTIN | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 1.99 | 34.8K | 17,500 | — | ↗ |
| 2019-08-29 | Blayney Douglas | Director | A-Award | A | Stock Option (right to buy) | 18,000 | 1.99 | 35.8K | 18,000 | — | ↗ |
| 2019-06-21 | O'Brien Peter Michael | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 25,000 | — | ↗ |
| 2019-06-21 | Moss David J | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 223,194 | — | ↗ |
| 2019-06-21 | MATSUI CONNIE | Director | — | D | Common Stock | 0 | 0.00 | — | 15,000 | — | ↗ |
| 2019-06-21 | Kelly Steven | Director | — | D | Common Stock | 0 | 0.00 | — | 12,500 | — | ↗ |
| 2019-06-21 | Gorgas Gregory D. | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 238,509 | — | ↗ |
| 2019-06-21 | Erbez Georgia | Director | — | D | Common Stock | 0 | 0.00 | — | 12,500 | — | ↗ |
| 2019-06-21 | EMANUELE ROBERT MARTIN | Director | — | D | Stock Option (Right to Buy) | 12,500 | 10.80 | 135.0K | 0 | — | ↗ |
| 2019-06-21 | Blayney Douglas | Director | — | D | Common Stock | 0 | 0.00 | — | 12,500 | — | ↗ |
| 2018-01-26 | Moss David J | 10% Owner | — | D | Warrant (Right to Buy) | 9,615 | 12.00 | 115.4K | 0 | — | ↗ |
| 2018-01-26 | Gorgas Gregory D. | Director / Officer / 10% Owner | — | D | Warrant (Right to Buy) | 2,884 | 12.00 | 34.6K | 0 | — | ↗ |
| 2017-06-30 | Moss David J | 10% Owner | — | D | Warrant (Right to Buy) | 31,250 | 8.00 | 250.0K | 0 | — | ↗ |
| 2017-06-30 | Gorgas Gregory D. | Director / Officer / 10% Owner | — | D | Warrant (Right to Buy) | 15,625 | 8.00 | 125.0K | 0 | — | ↗ |
| 2009-11-18 | TATUM JAMES G | Director | D-Return | D | Common Stock | 9,429 | 5.50 | 51.9K | 0 | — | ↗ |
| 2009-11-18 | SCHLIER BRIAN | Officer | D-Return | D | Common Stock | 15,000 | 5.50 | 82.5K | 0 | — | ↗ |
| 2009-11-18 | LAPIN STEVEN B | Director / Officer | D-Return | D | Common Stock | 195,665 | 5.50 | 1.08M | 0 | — | ↗ |
| 2008-01-08 | SCHLIER BRIAN | Officer | M-Exempt | D | Employee stock option (right to buy) | 15,000 | 4.10 | 61.5K | 0 | — | ↗ |
| 2007-08-08 | TATUM JAMES G | Director | A-Award | A | Stock Option (Right to Buy) | 500 | 10.62 | 5.3K | 500 | — | ↗ |
| 2007-06-14 | TATUM JAMES G | Director | S-Sale | D | Common Stock | 1,804 | 13.25 | 23.9K | 9,589 | — | ↗ |
| 2007-06-13 | LAPIN STEVEN B | Director / Officer | S-Sale | D | Common Stock | 225,000 | 13.28 | 2.99M | 195,665 | — | ↗ |
| 2007-06-12 | LAPIN STEVEN B | Director / Officer | M-Exempt | D | Stock Option (Right to buy) | 200,000 | 2.95 | 590.0K | 0 | — | ↗ |
| 2007-06-08 | TATUM JAMES G | Director | S-Sale | D | Common Stock | 1,036 | 13.30 | 13.8K | 12,393 | — | ↗ |
| 2007-06-06 | TATUM JAMES G | Director | M-Exempt | A | Common Stock | 500 | 6.89 | 3.4K | 13,429 | — | ↗ |
| 2007-06-04 | LAPIN STEVEN B | Director / Officer | M-Exempt | D | Employee Stock Option (Right to buy) | 50,000 | 2.95 | 147.5K | 200,000 | — | ↗ |
| 2007-06-01 | TATUM JAMES G | Director | S-Sale | D | Common Stock | 500 | 13.20 | 6.6K | 9,429 | — | ↗ |
| 2007-05-31 | TATUM JAMES G | Director | S-Sale | D | Common Stock | 2,000 | 13.45 | 26.9K | 9,929 | — | ↗ |
| 2007-05-16 | TATUM JAMES G | Director | S-Sale | D | Common Stock | 1,000 | 11.00 | 11.0K | 0 | — | ↗ |
| 2007-05-15 | TATUM JAMES G | Director | S-Sale | D | Common Stock | 398 | 10.86 | 4.3K | 1,000 | — | ↗ |
| 2007-05-14 | TATUM JAMES G | Director | S-Sale | D | Common Stock | 100 | 10.90 | 1.1K | 1,398 | — | ↗ |
| 2007-05-10 | TATUM JAMES G | Director | S-Sale | D | Common Stock | 502 | 11.25 | 5.6K | 1,498 | — | ↗ |
| 2006-12-20 | TATUM JAMES G | Director | A-Award | A | Stock Option (Right to buy) | 500 | 9.24 | 4.6K | 500 | — | ↗ |
| 2006-06-15 | TATUM JAMES G | Director | S-Sale | D | Common Stock | 160 | 13.25 | 2.1K | 9,429 | — | ↗ |
| 2005-11-01 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 2,000 | 6.75 | 13.5K | 95,671 | — | ↗ |
| 2005-10-05 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 440 | 7.20 | 3.2K | 97,671 | — | ↗ |
| 2005-09-15 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 930 | 7.50 | 7.0K | 98,111 | — | ↗ |
| 2005-09-14 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 1,882 | 7.77 | 14.6K | 99,229 | — | ↗ |
| 2005-09-13 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 2,714 | 7.20 | 19.5K | 101,111 | — | ↗ |
| 2005-09-09 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 1,700 | 7.00 | 11.9K | 103,825 | — | ↗ |
| 2005-09-08 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 286 | 7.20 | 2.1K | 105,525 | — | ↗ |
| 2005-08-31 | TATUM JAMES G | Director | A-Award | A | Stock Option (Right to Buy) | 500 | 6.89 | 3.4K | 4,000 | — | ↗ |
| 2005-08-12 | OSTER SHARON M | Director | M-Exempt | A | Common Stock | 1,000 | 5.99 | 6.0K | 23,273 | — | ↗ |
| 2005-08-09 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 2,958 | 7.20 | 21.3K | 105,811 | — | ↗ |
| 2005-08-08 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 2,976 | 7.20 | 21.4K | 108,769 | — | ↗ |
| 2005-08-05 | OSTER SHARON M | Director | M-Exempt | D | Stock Option (Right to Buy) | 500 | 4.91 | 2.5K | 7,000 | — | ↗ |
| 2005-06-13 | TATUM JAMES G | Director | P-Purchase | A | Common Stock | 1,000 | 6.00 | 6.0K | 11,929 | — | ↗ |
| 2004-11-17 | TATUM JAMES G | Director | P-Purchase | A | Common Stock | 929 | 5.80 | 5.4K | 10,929 | — | ↗ |
| 2004-09-01 | CRAWFORD JOHN JOSEPH | Director | P-Purchase | A | Common Stock | 4,000 | 5.50 | 22.0K | 111,745 | — | ↗ |
| 2004-08-10 | TATUM JAMES G | Director | P-Purchase | A | Common Stock | 500 | 5.09 | 2.5K | 2,000 | — | ↗ |
| 2004-08-10 | LAPIN STEVEN B | Director / Officer | P-Purchase | A | Common Stock | 213 | 5.00 | 1.1K | 11,123 | — | ↗ |
| 2004-08-05 | LAPIN STEVEN B | Director / Officer | P-Purchase | A | Common Stock | 245 | 5.00 | 1.2K | 10,910 | — | ↗ |
| 2004-06-18 | TATUM JAMES G | Director | A-Award | A | Stock Option (Right to Buy) | 500 | 4.91 | 2.5K | 3,500 | — | ↗ |
| 2004-06-18 | OSTER SHARON M | Director | A-Award | A | Stock Option (Right to Buy) | 500 | 4.91 | 2.5K | 5,000 | — | ↗ |
| 2004-06-18 | CRAWFORD JOHN JOSEPH | Director | A-Award | A | Stock Option (Right to Buy) | 500 | 4.91 | 2.5K | 27,667 | — | ↗ |
| 2004-06-14 | TATUM JAMES G | Director | P-Purchase | A | Common Stock | 1,000 | 4.90 | 4.9K | 10,000 | — | ↗ |
| 2004-05-17 | TATUM JAMES G | Director | P-Purchase | A | Common Stock | 1,000 | 4.91 | 4.9K | 9,000 | — | ↗ |
| 2004-05-11 | TATUM JAMES G | Director | P-Purchase | A | Common Stock | 1,000 | 4.91 | 4.9K | 8,000 | — | ↗ |
| 2004-03-08 | TATUM JAMES G | Director | P-Purchase | A | Common Stock | 1,000 | 5.18 | 5.2K | 7,000 | — | ↗ |
| 2003-12-12 | CRAWFORD JOHN JOSEPH | Director | M-Exempt | A | Common Stock | 30,000 | 2.95 | 88.5K | 96,145 | — | ↗ |
| 2003-12-10 | CRAWFORD JOHN JOSEPH | Director | G-Gift | D | Series I Preferred Stock | 3,550 | 12.00 | 42.6K | 62,003 | — | ↗ |
| 2003-12-08 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 3,200 | 5.25 | 16.8K | 66,145 | — | ↗ |
| 2003-12-04 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 800 | 5.10 | 4.1K | 69,345 | — | ↗ |
| 2003-12-03 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 700 | 5.25 | 3.7K | 70,145 | — | ↗ |
| 2003-11-14 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 800 | 5.03 | 4.0K | 71,045 | — | ↗ |
| 2003-11-12 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 1,008 | 5.25 | 5.3K | 71,845 | — | ↗ |
| 2003-11-07 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 300 | 5.25 | 1.6K | 73,053 | — | ↗ |
| 2003-11-05 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 1,400 | 5.30 | 7.4K | 74,353 | — | ↗ |
| 2003-09-15 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 3,600 | 4.70 | 16.9K | 75,753 | — | ↗ |
| 2003-09-12 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 1,500 | 4.65 | 7.0K | 79,753 | — | ↗ |
| 2003-09-11 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 700 | 4.67 | 3.3K | 81,553 | — | ↗ |
| 2003-09-10 | CRAWFORD JOHN JOSEPH | Director | S-Sale | D | Common Stock | 2,300 | 4.66 | 10.7K | 83,253 | — | ↗ |
| 2003-06-20 | TATUM JAMES G | Director | A-Award | A | Stock Option (Right to Buy) | 500 | 3.26 | 1.6K | 3,000 | — | ↗ |
| 2003-06-20 | OSTER SHARON M | Director | A-Award | A | Stock Option (Right to Buy) | 500 | 3.26 | 1.6K | 4,500 | — | ↗ |
| 2003-06-20 | CRAWFORD JOHN JOSEPH | Director | A-Award | A | Stock Option (Right to Buy) | 500 | 3.26 | 1.6K | 67,166 | — | ↗ |
Executive team
Top executives
Shares Outstanding
2.18M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Gregory D. Gorgas President, CEO, CFO, Secretary, Treasurer and Director | 520.0K | 242.5K | — | 240.0K | — | 58.0K | 1.06M | 22.63% | ↗ |
| 2 | 2023 | Gregory D. Gorgas President, CEO, CFO, Secretary, Treasurer and Director | 485.4K | 251.2K | — | 251.6K | — | 5.8K | 994.1K | 25.31% | ↗ |
| 3 | 2022 | President, CEO, CFO, Secretary, Treasurer and Director | 440.0K | 209.0K | — | — | — | 5.8K | 654.8K | 0.00% | ↗ |
| 4 | 2021 | President, CEO, CFO, Secretary, Treasurer and Director | 425.0K | 210.4K | — | 3.57M | — | 2.9K | 4.21M | 84.83% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gregory D. Gorgas | President, Chief Executive Officer, Secretary & Director | 876.9K | male |
| Mark E. Spring | Chief Financial Officer, Treasurer, Principal Financial Officer & Principal Accounting Officer | 226.0K | male |
| Andrew Yates | Senior Vice President & Chief Scientific Officer | — | — |
| Jason H. Baybutt | Senior Vice President of Finance | — | male |
| Steven D. Reich | Chief Medical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ARTL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
